1Drolet BA, Swanson EA, Frieden IJ, et al. Infantilehemangiomas : an emerging health issue linked to an increasedrate of low birth weight infants [J]. J Pediatr,2008,153 (5 ):712-715.
2L6aut6-Labrze C, Dumas de la Roque E, Hubiche T, et al.Propranolol for severe hemangiomas of infancy [J]. N Engl JMed, 2008, 358(24) : 2649-2651.
3Sans V, de la Roque ED,Berge J,et al. Propranolol for severeinfantile hemangiomas : follow-up report [J]. Pediatrics,2009,124(3) ; 423431.
4Buckmiller L, Dyamenahalli U, Richter GT. Propranolol forairway hemangiomas : case report of novel treatment [J].Laryngoscope, 2009, 119(10):2051-2054.
6Hogeling M, Adams S, Wargon O. A randomized controlled trialof propranolol for infantile hemangiomas [J]. Pediatrics, 2011,128(2): 259-266.
7Price CJ, Lattouf G, Baum B, et al. Propranolol vscorticosteroids for infantile hemangiomas: a multicenterretrospective analysis [J]. Arch Dermatol, 2011, 147 ( 12):1371-1376.
8Peridis S,Pilgrim G,Athanasopoulos I,et al. A meto-analysis onthe effectiveness of propranolol for the treatment of infantile airwayhaemangiomas [J]. Int J Pediatr Otorhinolaryngol, 2011,75(4): 455460.
2Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe haemangiomas of infancy'. N Engl J Med, 2008,358 (24) :2649-2651.
3Kenneth J,Thomas D. Analysis of relative gene expression data using real-time quantitative PCR and the 2^△△C1 method. Methods,2001,25(2) :402-408.
4Nguyen J, Fay A. Pharmacological therapy for periocular infam tile haemangiomas:a review of the literature. Semin Othalmol, 2009,24(3) : 178-184.
5Leaute-Labrbze C, Taieb A. Efficacy of beta-blockers in infantile haemangiomas: the physiopathological significance and therapeutic consequences. Ann Dermatol Venerol, 2008, 135 (12) :860-862.
6Annabi B, Lachambre MP, Plouffe K, et al. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res,2009,60(4) :438-445.
7Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 1995,333 (26) : 1757- 1763.
8Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor(VEGF) and its receptors. FASEB J, 1999, 13(1):9-22.
9Karkainen MJ,Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogence. Oncogence, 20(15,19 (49) : 5598-5605.
10Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGF-2 activates human leuke-miae cell growth and migration. J Clin Invest,2003,106(4) :511 -521.
2Gentile M,Recchia AG,Mazzone C,et al.Perspectives in the treatment of multiple myeloma[J].Expert Opin Biol Th,2013,13(1):1-22.
3Wildes TM,Vij R,Petersdorf SH,et al.New Treatment Approaches for Older Adults with Multiple Myeloma[J].J Geriatr Oncol,2012,3(3):279-290.
4Shi M,Liu D,Yang Z,et al.Central and peripheral nervous systems:master controllers in cancer metastasis[J].Cancer Metastasis Rev,2013,32(3/4):603-621.
5Mahindra A,Hideshima T,Anderson KC.Multiple myeloma:biology of the disease[J].Blood Rev,2010,24(1):5-11.
6Minnema MC,Van der Spek E,Van de Donk NW,et al.New developments in the treatment of patients with multiple myeloma[J].Neth J Med,2010,68(1):24-32.
7Leaute-Labreze C,Dumas de la Roque E,Hubiche T,et al.Propranolol for severe hemangiomas of infancy[J].N Engl J Med,2008,358(24):2649-2651.
8Baliga BC,Kumar S.Role of bcl-2 family of proteins in malignancy[J].Hematol Onco1,2002,20(2):63-74.
9Nika N.Bel-2 family proteins:critical checkpoints of apoptitie cell death[J].Clin Cancer Res,2007,13(24):7254-7263.
10Antonsson B,Conti F,Ciavatta A,et al.Inhibition of Bax channel-forming activity by Bcl-2[J].Science,1997,277(5324):370-372.
